TrialGynecologic oncology2015

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

Kathleen N Moore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.